Exchange: NASDAQ·Updated 04:15 PM EST
CRDF logo

CRDF Cardiff Oncology Inc

$0.8549
$0.0074
(0.87%)
Today
Closed $0.839
$0.0159
(1.90%)
After Hours
Reported EarningsNov 12
Mkt Cap$65.85M
Vol853,181.00

About CRDF

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The firm is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
75

Extremely Bullish Sentiment

How do you feel about CRDF?

richapd
$CRDF The 30 mg arm had 5 surgical conversions which is a big deal because data shows that the mPFS from the date of conversion is 20 months in one study. Surgical conversions are usually not performed until after 3-5 months of chemotherapy bringing the expected mPFS from their initiation on trial to 23-25 months for those 5 patients. Furthermore, the 30mg arm CR's(without surgical conversion) will have a much higher mPFS because their tumor bulk was driven down more logs volume than the PR's(seen with chemo/bev alone), thus requiring much longer time for regrowth to the point of progression(>5mm size tumor). Like Bull Run4 said, it would be nice/needful/expedient... to see some data granularity reported. I can't but believe there are some suitors interested in this singular data. Also, reviewing the toxicity data is extraordinary that there was essentially no added toxicity to the chemo/bev alone. That points to the exquisite specificity targeting PLK1 and not PLK's 2-5. The lack of toxicity allows ONV to be combined with anything essentially.
26
jerrybe5000
$CRDF It is somewhat nuts to see it at such a low valuation. I just listened to the UBS call and slides from the website. They actually delivered exactly what the FDA wanted from them in terms of 004 study. They got fast track. They got a p3 registrational study with AA attached ready to go. Soon with blessing from EMA. What else do they need? Two orphan drug designation for Onvan as monotherapy. The spider plots and data, albeit on small sample, are as compelling as one could hope for. Yes, N=18, but still got the earlier Onsemble results that line up exactly. So it is not an artefact of 004. The MOA is well established. Synergistic action with Bev and Irinotecan. Everything lines up. Yes valued at less than $40M above cash value. Just absurd in my book. I said I wouldn't add but I think funding is going to be secured. That validation will give significant lift to the stock. Maybe a full blown BO (if board not greedy), maybe a partnership. It has to happen.
1
13
Lord_Andrew_London
$CRDF Today's news are a clear signal that the product is recognized effective at institutional level. Now it's time complete what Is Needed to move forward
15
DD_investments
$CRDF I’m pretty confident they have a home run here with onvansertib. All the possible synergies is what gets me excited the most, especially especially with how easy it is to add to existing treatments. The mechanism of action is well understood, Plk1 inhibitors themselves are not new but before this they always had issues with tolerance. Improving patient outcomes is what everyone should want here and it’s clear that’s what onvansertib does
14
rag2riches
$CRDF did a little digging. Mani was an analyst at UBS. UBS been trading CRDF since 2020 but only have two 13Fs reported with 4.5k then 3.7k shares held. Mani joined CRDF in 2021. In 2021 thru 2026 UBS gets more active with CRDF now starting to pump and dump shares In feb 2025 UBS disclosed 283k shares and continues to dump until Jan 2026 Mani takes interim CEO role Jan 2026 on which UBS held 87k but then 4 months later just after mani is announced permnant CEO, UBS 13f shows 400k shares held and then 638k shared held the the following 13F filing. Not making any claims here but this recorded trading pattern is highly suspicious. Mani and UBS differently having private discussions and this UBS conference could be a MASSIVE ANNOUNCEMENT just based on the fact how UBS exponentially bought shares since Mani took over and now her presenting at their event. Fasten your seatbelts
3
8
SlayDaddie
$CRDF How I view the recent huge volume. 1. Big bear holdings may have taken out their short holdings ahead of the incoming catalyst. 2. Big bulls accumulating. Either way, it’s another good sign for me. 🔥
1
6
Cossandon
$CRDF If I were to summarize the message of what Mani just communicated in the USB conferenece it would be this "We think the data have crossed the threshold from promising to reproducible. Now we need the capital to demonstrate that conclusively in Phase 3. Come be our partner!"
13
rag2riches
$CRDF shorts trying with all their might to keep this below 1. This is unsustainable to them becausd as soon as it kisses 1 its going to fly to 1.30.
2
6
Zach_03
$CRDF This is huge news, hopefully helps put us on the map more for partners. We still have the “backup” option to dilute, but we know they are going to continue be actively looking for a partner to raise at a higher price
11
biohuntress
$CRDF I want to hear unambiguous updated PFS ( as of Nov... no March rehash)....I suspect CRDF has EMA greenlight and they're looking for a partner in Europe at UBS......Rasonque, despite severe toxicities got FDA Breakthrough Status....if mPFS hasn't been reached by Nov, Onva's low toxicity should qualify it for Breakthrough ....that would be a complete package and icing on the cake
1
11
richapd
$CRDF What is baffling to me as a simple minded med onc is why BP and tutes aren't clamoring for a company whose agent, ONV, is sporting a doubling of mPFS in a stubborn mCRC RAS+ population. That type of improvement in the oncology world is incredibly noteworthy. Am I a conspiracy theorist or is there some reason this is purposely being held down or simply is this a stock hidden under a rock?
13
BullRun4
$CRDF 1. Where the financial advantage comes from Fast Track: GRANTED More frequent FDA interaction. Potential rolling NDA submission. Does not authorize commercial sales. Accelerated Approval: Potential Future Pathway Earlier potential commercial launch. Revenue while confirmatory trials continue. Earlier opportunity to establish market adoption. A pharmaceutical partner evaluating Cardiff today sees a Phase 3 development opportunity with Fast Track designation. If Cardiff could establish a credible Accelerated Approval pathway, the proposition changes: Potentially earlier commercialization. Earlier revenue generation. Reduced time before commercial validation. Greater strategic value to a pharmaceutical company. Potentially stronger licensing and acquisition negotiations.
10
jerrybe5000
$CRDF big pharma has to step in. It’s the obvious next validation step. And the only reasonable one to fund this. Today was a confirmation that 004 was a resounding success. To my eyes. And beauty is in the eye of the beholder. So now we need BP to see what us longs see. If they don’t, we’ll, I will have to reassess my bullishness on the treatment front. Period.
9
Cutlass
$CRDF Benefits of Orphan Drug Designation 1. Tax Credits Sponsors can receive tax credits for up to 25% of qualified clinical trial expenses. 2. Exemption from User Fees Waiver of the Prescription Drug User Fee Act (PDUFA) fees, which can exceed $4 million. 3. Market Exclusivity Seven years of market exclusivity in the U.S. after approval, preventing competition for the same indication. 4. Regulatory Assistance Access to specialized guidance from the FDA to help design clinical trials and navigate the approval process. Additional Incentives Research Grants: Eligibility to compete for grants from the Office of Orphan Products Development to support clinical studies. Protocol Assistance: Reduced fees for scientific advice and protocol assistance specifically for orphan medicines. Conditional Approval: Potential access to conditional marketing authorization in the EU, allowing earlier access to the market.
12
jerrybe5000
$CRDF market cap of $50M. Offer $150M and the board has to accept a 200% return. It’s so cheap it hurts. This is a company with a p3 ready asset with AA attached to it. Just mind boggling how low the valuation has gotten.
1
9
JN75
$CRDF Bag finally fully loaded on yesterday's dips. LFG Mani. Earn your keep!!! GL Bulls, as Market tries to read NVDA's earnings....we wait PAYtiently.
6
rag2riches
$CRDF FDA agreed phase 3 trial design with ORR as an accelerated approval pathway and now FAST TRACK designation with the FDA and Positive Phase 2 data. Guys, it cant get any easier than this. The funding is going to come one way or another. Your backs are about to be blown when they announce their financing and at that point it will be too late. The sheep will help run the price up once funding or partnership is secured and announced. Im now starting to think what color snow mobile i want and im lucky i may have it before it snows. Full circle moment for Mani as a UBS analyst now presenting today and sitting on an arguably new SoC for CRC.
9
Cutlass
$CRDF Upcoming Events Cardiff management will present at the UBS Global Biopharma Conference and participate in one-on-one investor meetings on November 16–17, 2026. Dr. Mohindru’s presentation is scheduled for November 16 at 2:40 p.m. GMT. A live webcast and replay will be available in the “Events” section of the Cardiff Oncology(CRDF) website. Updated data from an investigator-sponsored clinical trial in CMML will be presented at the American Society of Hematology (“ASH”) Annual Meeting on December 13, 2026.
11
BullRun4
$CRDF Good morning Cardiff investors I would like Cardiff to disclose tomorrow an updated swimmer plot and formal DoR analysis, including the number of responders still responding and the median DoR. If the longer-term follow-up confirms that the responses are durable across a meaningful proportion of patients, that could be a major differentiator. These are definitely exciting times as we wait for additional data and news on potential partnerships!
9
Mdmsi1
$CRDF Next few months will be very interesting, the way I see it we may possibly have quite a few catalysts. 1-EMA feedback on phase 3 2-FDA possible breakthrough designation 3-UBS bio conference 4-Phase 3 funding or partnership 5-Additional phase 2 data Let’s hope they don’t f… it up.
10

Advertisement|Remove ads.